Precision BioSciences (DTIL) Competitors $4.51 +0.20 (+4.64%) As of 02:05 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock DTIL vs. EPRX, ENGN, TLSA, CTMX, OGI, GNFT, FDMT, IPHA, VTYX, and DERMShould you be buying Precision BioSciences stock or one of its competitors? The main competitors of Precision BioSciences include Eupraxia Pharmaceuticals (EPRX), enGene (ENGN), Tiziana Life Sciences (TLSA), CytomX Therapeutics (CTMX), Organigram Global (OGI), GENFIT (GNFT), 4D Molecular Therapeutics (FDMT), Innate Pharma (IPHA), Ventyx Biosciences (VTYX), and Journey Medical (DERM). These companies are all part of the "pharmaceutical products" industry. Precision BioSciences vs. Its Competitors Eupraxia Pharmaceuticals enGene Tiziana Life Sciences CytomX Therapeutics Organigram Global GENFIT 4D Molecular Therapeutics Innate Pharma Ventyx Biosciences Journey Medical Eupraxia Pharmaceuticals (NASDAQ:EPRX) and Precision BioSciences (NASDAQ:DTIL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability. Do analysts rate EPRX or DTIL? Eupraxia Pharmaceuticals presently has a consensus target price of $11.00, suggesting a potential upside of 99.82%. Precision BioSciences has a consensus target price of $47.00, suggesting a potential upside of 949.11%. Given Precision BioSciences' higher possible upside, analysts clearly believe Precision BioSciences is more favorable than Eupraxia Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eupraxia Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Precision BioSciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better valuation & earnings, EPRX or DTIL? Precision BioSciences has higher revenue and earnings than Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Precision BioSciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEupraxia PharmaceuticalsN/AN/A-$25.50M-$0.76-7.24Precision BioSciences$68.70M0.72$7.17M-$2.01-2.23 Which has more volatility and risk, EPRX or DTIL? Eupraxia Pharmaceuticals has a beta of 1.55, meaning that its stock price is 55% more volatile than the S&P 500. Comparatively, Precision BioSciences has a beta of 1.43, meaning that its stock price is 43% more volatile than the S&P 500. Do institutionals & insiders believe in EPRX or DTIL? 38.0% of Precision BioSciences shares are held by institutional investors. 4.0% of Precision BioSciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media favor EPRX or DTIL? In the previous week, Eupraxia Pharmaceuticals had 2 more articles in the media than Precision BioSciences. MarketBeat recorded 3 mentions for Eupraxia Pharmaceuticals and 1 mentions for Precision BioSciences. Eupraxia Pharmaceuticals' average media sentiment score of 1.43 beat Precision BioSciences' score of 0.28 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eupraxia Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Precision BioSciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is EPRX or DTIL more profitable? Eupraxia Pharmaceuticals has a net margin of 0.00% compared to Precision BioSciences' net margin of -42.99%. Precision BioSciences' return on equity of -69.26% beat Eupraxia Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Eupraxia PharmaceuticalsN/A -367.73% -112.23% Precision BioSciences -42.99%-69.26%-29.30% SummaryEupraxia Pharmaceuticals and Precision BioSciences tied by winning 8 of the 16 factors compared between the two stocks. Get Precision BioSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for DTIL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DTIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DTIL vs. The Competition Export to ExcelMetricPrecision BioSciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$49.68M$2.90B$5.49B$8.93BDividend YieldN/A2.44%5.24%4.04%P/E Ratio-2.2320.9327.1520.17Price / Sales0.72191.67380.3794.17Price / CashN/A41.7026.2128.59Price / Book0.657.487.995.60Net Income$7.17M-$55.04M$3.17B$248.41M7 Day Performance8.47%5.32%3.51%6.03%1 Month Performance-18.40%2.44%2.80%7.70%1 Year Performance-51.83%5.19%34.00%20.86% Precision BioSciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DTILPrecision BioSciences4.4834 of 5 stars$4.51+4.6%$47.00+942.1%-53.2%$50.02M$68.70M-2.24200EPRXEupraxia Pharmaceuticals2.5234 of 5 stars$5.76+8.7%$11.00+91.0%+120.2%$190.57MN/A-7.5829Positive NewsGap UpHigh Trading VolumeENGNenGene2.8002 of 5 stars$3.64-0.5%$23.29+539.7%-58.4%$187.04MN/A-2.2131TLSATiziana Life Sciences0.6786 of 5 stars$1.58-1.3%N/A+84.3%$186.96MN/A0.008Positive NewsCTMXCytomX Therapeutics3.908 of 5 stars$2.27+0.9%$5.33+134.9%+83.7%$181.40M$138.10M4.73170OGIOrganigram Global0.5328 of 5 stars$1.35flatN/A-12.3%$180.82M$117.47M13.50860News CoverageGap DownGNFTGENFIT1.9822 of 5 stars$3.73+3.2%$13.00+249.0%-11.4%$180.49M$67.00M0.00120Positive NewsFDMT4D Molecular Therapeutics2.2647 of 5 stars$3.71-3.4%$29.56+696.6%-81.3%$177.89M$40K-1.17120IPHAInnate Pharma2.5384 of 5 stars$1.82-1.9%$11.00+506.1%-10.1%$170.53M$21.77M0.00220Positive NewsGap DownVTYXVentyx Biosciences2.383 of 5 stars$2.14-8.5%$10.00+367.3%-6.4%$166.52MN/A-1.2230DERMJourney Medical1.9078 of 5 stars$7.18+0.6%$9.50+32.3%+36.5%$166.33M$56.13M-18.4190Analyst Downgrade Related Companies and Tools Related Companies Eupraxia Pharmaceuticals Alternatives enGene Alternatives Tiziana Life Sciences Alternatives CytomX Therapeutics Alternatives Organigram Global Alternatives GENFIT Alternatives 4D Molecular Therapeutics Alternatives Innate Pharma Alternatives Ventyx Biosciences Alternatives Journey Medical Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DTIL) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredNobel Prize Material Finally Goes CommercialA Nobel Prize–winning material just got its biggest breakthrough in 30 years. A little-known company has cr...True Market Insiders | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Precision BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Precision BioSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
